The effects of preserved red blood cells on the severe adverse events observed in patients infused with hemoglobin based oxygen carriers

被引:7
作者
Valeri, C. Robert
Ragno, Gina
机构
[1] NBRL Inc., Boston, MA
[2] NBRL, Inc., Plymouth, MA 02360
来源
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY | 2008年 / 36卷 / 01期
关键词
liquid preserved RBC stored at 4 degrees C for 2 weeks; frozen deglycerolized RBC stored at 4 degrees C for 2 weeks; transfusion related acute lung injury (TRALI); leukoreduced and washed deglycerolized RBC;
D O I
10.1080/10731190701857736
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The severe adverse events observed in patients who received hemoglobin based oxygen carriers (HBOCs) were associated with the Ringer's D.L lactate resuscitative solution administered and to the excipient used in the HBOCs containing Ringer's D,L lactate and the length of storage of the preserved RBC administered to the patient at the time that the HBOCs were infused. This paper reports the quality of the red blood cells preserved in the liquid state at 4 degrees C and that of previously frozen RBCs stored at 4 degrees C with regard to their survival, function and safety. Severe adverse events have been observed related to the length of storage of the liquid preserved RBC stored at 4 degrees C prior to transfusion. The current methods to preserve RBC in the liquid state in additive solutions at 4 degrees C maintain their survival and function for only 2 weeks. The freezing of red blood cells with 40% W/V glycerol and storage at -80 degrees C allows for storage at -80 degrees C for 10 years and following thawing, deglycerolization and storage at 4 degrees C in the additive solution (AS-3, Nutricel) for 2 weeks with acceptable 24 hour posttransfusion survival, less than 1% hemolysis, and moderately impaired oxygen transport function with no associated adverse events. Frozen deglycerolized RBCs are leukoreduced and contain less than 5% of residual plasma and non-plasma substances. Frozen deglycerolized RBCs are the ideal RBC product to transfuse patients receiving HBOCs.
引用
收藏
页码:3 / 18
页数:16
相关论文
共 38 条
[1]   Extended storage of AS-1 and AS-3 leukoreduced red blood cells for 15 days after deglycerolization and resuspension in AS-3 using an automated closed system [J].
Bandarenko, N ;
Hay, SN ;
Holmberg, J ;
Whitley, P ;
Taylor, HL ;
Moroff, G ;
Rose, L ;
Kowalsky, R ;
Brumit, M ;
Rose, M ;
Sawyer, S ;
Johnson, A ;
McNeil, D ;
Popovsky, MA .
TRANSFUSION, 2004, 44 (11) :1656-1662
[2]   Successful in vivo recovery and extended storage of additive solution (AS)-5 red blood cells after deglycerolization and resuspension in AS-3 for 15 days with an automated closed system [J].
Bandarenko, Nicholas ;
Cancelas, Jose ;
Snyder, Edward L. ;
Hay, Shauna N. ;
Rugg, Neeta ;
Corda, Tammy ;
Joines, Amy D. ;
Gormas, Jennifer F. ;
Pratt, Gayle P. ;
Kowalsky, Richard ;
Rose, Michael ;
Rose, Leslie ;
Foley, Jim ;
Popovsky, Mark A. .
TRANSFUSION, 2007, 47 (04) :680-686
[3]   RETRACTED: The association between duration of storage of transfused red blood cells and morbidity and mortality after reoperative cardiac surgery (Retracted Article) [J].
Basran, Sukhjeewan ;
Frumento, Robert J. ;
Cohen, Allison ;
Lee, Samuel ;
Du, Yuling ;
Nishanian, Ervant ;
Kaplan, Harold S. ;
Stafford-Smith, Mark ;
Bennett-Guerrero, Elliott .
ANESTHESIA AND ANALGESIA, 2006, 103 (01) :15-20
[4]  
BEUTLER E, 1969, J LAB CLIN MED, V74, P300
[5]   Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt [J].
Blumberg, N .
TRANSFUSION, 2005, 45 (02) :33S-39S
[6]  
Dunne James R, 2004, Surg Infect (Larchmt), V5, P395, DOI 10.1089/sur.2004.5.395
[7]   Measures to prevent TRALI [J].
Engelfriet, C. P. ;
Reesink, H. W. ;
Wendel, S. ;
Biagini, S. ;
Trigo, F. ;
Fontao-Wendel, R. ;
Taaning, E. ;
Jorgensen, J. ;
Riisom, K. ;
Krusius, T. ;
Koskinen, S. ;
Kretschmer, V. ;
Karger, R. ;
Lawlor, E. ;
Okazaki, H. ;
Charlewood, R. ;
Brand, A. ;
Solheim, B. G. ;
Flesland, O. ;
Letowska, M. ;
Zupanska, B. ;
Muniz-Diaz, E. ;
Senn, M. ;
Mansourri-Taleghani, B. ;
Chapman, C. E. ;
Massey, E. ;
Navarrete, C. ;
Win, N. ;
Williamson, L. M. ;
Stainsby, D. ;
Kleinman, S. ;
Kopko, P. M. ;
Silva, M. ;
Shulman, I. ;
Hollness, L. .
VOX SANGUINIS, 2007, 92 (03) :258-277
[8]   Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery [J].
Fransen, E ;
Maessen, J ;
Dentener, M ;
Senden, N ;
Buurman, W .
CHEST, 1999, 116 (05) :1233-1239
[9]   Proceedings of a consensus conference: Towards an understanding of TRALI [J].
Goldman, M ;
Webert, KE ;
Arnold, DM ;
Freedman, J ;
Hannon, J ;
Blajchman, MA .
TRANSFUSION MEDICINE REVIEWS, 2005, 19 (01) :2-31
[10]  
GRAHMER C, 2006, VOX SANG, V90, P40